Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Veeva posted Q2 EPS of $2.35 and revenue of $927.96 million, beating consensus. It raised fiscal 2027 adjusted EPS guidance to $9.21 and revenue outlook to $3.682B-$3.687B. Pre-market shares rose 11.5% to $273.00.
Veeva Systems reported better-than-expected second-quarter results and raised FY27 guidance above estimates, while Revolution Medicines said the FDA approved Rasonque for metastatic pancreatic adenocarcinoma. Pulse Biosciences was added to a bullish analyst call.
Needham raised its Veeva Systems price target to $310.00 per share from $270.00.